/ATGGF
ATGGF Stock - Actinogen Medical Limited
Healthcare|BiotechnologyOTC
$0.04+0.00%
+$0.00 (+0.00%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.72
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.04
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ATGGF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.04 – $0.04
TARGET (TP)$0.05
STOP LOSS$0.04
RISK/REWARD1:Infinity
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.19
52W High$0.04
52W Low$0.01
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.49M | $9.93M | $4.89M | $3.64M | $1.98M |
| Gross Profit | $5.49M | $9.93M | $4.48M | $3.24M | $1.60M |
| Gross Margin | 100.0% | 100.0% | 91.7% | 89.0% | 80.5% |
| Operating Income | $-14,932,044 | $-12,838,991 | $-10,579,545 | $-9,132,688 | $-3,533,144 |
| Net Income | $-14,732,263 | $-13,044,282 | $-10,752,270 | $-9,497,370 | $-3,915,067 |
| Net Margin | -268.4% | -131.3% | -220.0% | -260.9% | -197.3% |
| EPS | $-0.00 | $-0.01 | $-0.01 | $-0.01 | $-0.00 |
Company Overview
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ATGGFBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q3 2025
EPS Surprise History
Q4 21
No data
Q2 22
No data
Q4 22
No data
Q2 23
No data
Q2 24
No data
Q4 24
No data
Q1 25
No data
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 23, 2026 | — | — | — | — |
Q3 2025 | Aug 31, 2025 | — | $-0.00 | — | — |
Q1 2025 | Feb 24, 2025 | — | $-0.17 | — | — |
Q4 2024 | Oct 29, 2024 | — | $-0.00 | — | — |
Q2 2024 | Apr 30, 2024 | — | $-0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.00 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.00 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.00 | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.00 | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.00 | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.00 | — | — |
Q4 2016 | Dec 31, 2016 | — | $-0.00 | — | — |
Q2 2016 | Jun 30, 2016 | — | $-0.00 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ATGGF
What is ATGGF's current stock price?
Actinogen Medical Limited (ATGGF) is currently trading at $0.04 per share. The stock has moved +0.00% today.
What is the analyst price target for ATGGF?
No analyst price targets are currently available for this stock.
What sector is Actinogen Medical Limited in?
Actinogen Medical Limited operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ATGGF's market cap?
Actinogen Medical Limited has a market capitalization of $0.13 billion, making it a small-cap company.
Does ATGGF pay dividends?
No, Actinogen Medical Limited does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBSEM
BioStem Technologies, Inc.
$4.24
Mkt Cap: $0.1B
CLTEF
Calliditas Therapeutics AB (publ)
$0.55
Mkt Cap: $0.0B
HBPCF
Helix BioPharma Corp.
$1.73
Mkt Cap: $0.1B
INNMF
Amplia Therapeutics Limited
$0.08
Mkt Cap: $0.0B
NICXF
Nicox S.A.
$0.30
Mkt Cap: $0.0B
PHYOF
IXICO plc
$0.07
Mkt Cap: $0.0B
PRNAF
Alterity Therapeutics Limited
$0.01
Mkt Cap: $0.1B
RLFTY
MindMaze Therapeutics Holding S.A. Sponsored ADR
$3.65
Mkt Cap: $0.0B
VICP
Vicapsys Life Sciences, Inc.
$1.50
Mkt Cap: $0.0B
ZIVO
ZIVO Bioscience, Inc.
$9.98
Mkt Cap: $0.0B
Explore stocks similar to ATGGF for comparison